Follow us
EN
EN

One of the main goals of Life4me+ — is to prevent new cases of HIV and other STIs, hepatitis C and tuberculosis.

The app helps to establish anonym communication between physicians and HIV-positive people. It allows you to conveniently organize your medication intake timetable and set concealed and personalized reminders.

All news

Archive

✕
10 August 2017
7000
Mylan Is To Provide India With HIV Drugs On Lower Price

Mylan Is To Provide India With HIV Drugs On Lower Price

Mylan will provide India with Avonza, an antiretroviral drug, recommended by the WHO as an alternative first-line regimen for people living with HIV. The drug will be realised in India at lower cost than in the other countries, Mylan provided the medicines. The president ...
9 August 2017
8211
Smart PrEP System Trial

Smart PrEP System Trial

Biologists from the Cook County Health and Hospitals System are searching for nearly 100 men who have sex with men (MSM) without HIV between 16 and 24 years old to their “smart PrEP” system trial. System can show to the treating doctor in the real time if his patient has ...
8 August 2017
7865
Australia Is To start PrEP Program

Australia Is To start PrEP Program

Australian Federal government health body approved listing of PrEP on the Pharmaceutical Benefits Scheme (PBS) due to a bit number of australians who are at high risk of becoming HIV positive. Truvada was approved by the Therapeutic Goods Administration to be used in Australia ...
7 August 2017
8787
Mytesi is Effective For Diarrhea by HIV-positive People

Mytesi is Effective For Diarrhea by HIV-positive People

Mytesi (Fulyxaq) anti-diarrheal 125 mg pill, taken twice a day, in the only approved drug by the FDA for treating noninfectious diarrhea by people living with HIV showed great efficiency in the number of clinical trials and the results of the research were presented at the ...
7 August 2017
8088
Efficiency of PrEP Usage by MSM

Efficiency of PrEP Usage by MSM

The article of belgian and dutch researchers “Pre-exposure prophylaxis (PrEP) for men who have sex with men in Europe: review of evidence for a much needed prevention tool” was published in print in the beginning of August, 2017 in Sexually transmitted Infections journal.
4 August 2017
10094
Monthly Injections Can Become Alternative to ARV Drugs

Monthly Injections Can Become Alternative to ARV Drugs

The results of the research, which were represented at the International AIDS Society meeting in France shows that instead of daily ARV drugs intake, a person with HIV positive status could have an injection with all the needed antiretroviral drugs once a month
4 August 2017
8953
Towards Ending AIDS — Dispatch From The Battle Front

Towards Ending AIDS — Dispatch From The Battle Front

July turned out to be rich in notable events in the field of fighting against HIV/AIDS — UNAIDS issued the latest progress report, and International AIDS Society (IAS) held HIV Science conference in Paris whereas World Health Organization urges about HIV drug resistance ...
4 August 2017
7842
World’s largest PrEP Trial Start Was Announced in England

World’s largest PrEP Trial Start Was Announced in England

NHS England announced the start of PrEP trial by people at high risk of becoming HIV positive. Transgender, bisexual men and women, members of LGBT communities, people whose partner lives with HIV but without therapy - about 10 000 people will become the participants of ...
3 August 2017
9335
New Treatments for Multidrug-Resistant and Extensively Drug-Resistant TB (MDR- and XDR-TB)

New Treatments for Multidrug-Resistant and Extensively Drug-Resistant TB (MDR- and XDR-TB)

The results of three studies on finding a treatment for multidrug-resistant and extensively drug-resistant tuberculosis (MDR- and XDR-TB) , led by researchers from Medecins Sans Frontieres, were published in the Emerging Infectious Diseases journal.
3 August 2017
7409
Merck Represented the DRIVE-AHEAD Study of Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Doravirine

Merck Represented the DRIVE-AHEAD Study of Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Doravirine

Merck company represented the DRIVE-AHEAD study of the non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine in one pill, which should be taken once in a day before or after meal at the 9th International AIDS Society Conference on HIV Science (IAS 2017). The ...
We use cookies on this site to enhance your experience.
By clicking any button on this website you are giving your consent for us to set cookies.